Skip to main content
. 2021 Feb 24;4(2):e210070. doi: 10.1001/jamanetworkopen.2021.0070

Table 1. Baseline Demographic Characteristics, Veterans Diagnosed With Prostate Cancer 2010-2017.

Characteristic Treated with ADT, No. (%)a
Yes (n = 22 700) No (n = 67 794)
Age, median (IQR), y 67 (63-74) 65 (61-69)
Race
White 14 315 (66.0) 43 857 (67.7)
African American 6864 (31.7) 19 346 (29.9)
Otherb 507 (2.3) 1536 (2.4)
Year category
2010-2011 6262 (27.6) 19 948 (29.4)
2012-2013 5430 (23.9) 17 069 (25.2)
2014-2015 5445 (24.0) 15 863 (23.4)
2016-2017 5563 (24.5) 14 914 (22.0)
No. of PCP visits over study period, median (IQR) 5 (4-8) 5 (3-7)
Poverty index above median 14 501 (64.3) 41 975 (62.3)
Prior ASCVD 4772 (21.0) 10 483 (15.5)
Smoking status
Never 6027 (33.9) 17 894 (34.1)
Current 6286 (35.3) 18 312 (34.9)
Former 5485 (30.8) 16 307 (31.1)
BMI, median (IQR) 28.4 (24.9,32.5) 28.7 (25.6,32.4)
Overweight (BMI ≥25) 15 161 (74.3) 47 852 (79.4)
Obese (BMI >30) 7963 (39.0) 24 058 (39.9)
Disease stage
Low risk 721 (3.3) 25 591 (39.0)
Intermediate risk 5744 (26.2) 20 221 (30.8)
High risk 10 347 (47.3) 18 740 (28.6)
Metastatic or node positive 5079 (23.2) 1048 (1.6)
PSA, ng/mL
<10 10 117 (47.2) 52 806 (82.7)
10-20 4582 (21.4) 8067 (12.6)
≥20 6731 (31.4) 2944 (4.6)
Gleason score
≤6 1326 (6.5) 28 226 (46.0)
7 8159 (39.9) 28 170 (45.9)
8-10 10 986 (53.7) 5026 (8.2)
T category
T1-T2a 12 431 (64.0) 43 419 (72.5)
T2b 1240 (6.4) 1303 (2.2)
≥T2c 5750 (29.6) 15 142 (25.3)

Abbreviations: ADT, androgen deprivation therapy; ASCVD, atherosclerotic cardiovascular disease; BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); IQR, interquartile range; PCP, primary care physician; PSA, prostate specific antigen.

SI conversion: To convert PSA to micrograms per liter, multiply by 1.

a

Unless otherwise indicated, data are expressed as number (percentage) of patients with recorded data.

b

Other includes American Indian or Alaska Native, Asian, Native Hawaiian or other Pacific Islander, and multiple categories.